President Trump announced new 100 percent import taxes on branded pharmaceuticals. These tariffs begin October 1. Companies building US manufacturing plants will be exempt. Major drugmakers like Merck and Lilly saw slight share increases. Analysts predict minimal impact on large firms. Smaller drugmakers might face vulnerability. Generic medicines remain unaffected by this new policy.